Isi Artikel Utama

Ariska Deffy Anggarany
Wafa
Rifaldi Saputra

Page: 2223-2234

Abstrak

Pendahuluan: Gangguan fungsi ginjal memengaruhi farmakokinetik berbagai antibiotik yang dieliminasi melalui jalur renal, sehingga berisiko menyebabkan akumulasi obat, toksisitas, atau kegagalan terapi jika dosis tidak disesuaikan. Variabilitas respons antibiotik pada populasi ini masih menjadi tantangan klinis karena dipengaruhi oleh kompleksitas parameter farmakokinetik/farmakodinamik (PK/PD), derajat gangguan ginjal, komorbiditas, dan strategi pemberian dosis. Tujuan: Tinjauan sistematis ini bertujuan untuk mengeksplorasi hubungan antara parameter farmakokinetik klinis dengan variabilitas respons antibiotik pada pasien dewasa dengan gangguan fungsi ginjal serta mengidentifikasi strategi individualisasi terapi berbasis PK/PD yang dapat diimplementasikan. Metode: Pencarian literatur dilakukan melalui PubMed/MEDLINE, Scopus, Embase, dan Cochrane Library (2016-2026) dengan pedoman PRISMA 2020. Studi pada pasien dewasa (≥18 tahun) dengan gangguan fungsi ginjal yang melaporkan parameter PK/PD dan luaran klinis diikutsertakan. Sintesis naratif dilakukan terhadap 18 artikel yang memenuhi kriteria inklusi. Hasil: Fungsi ginjal merupakan determinan utama paparan antibiotik, terutama untuk obat yang dieliminasi melalui ginjal. Parameter PK/PD seperti AUC/MIC, konsentrasi lembah, dan %fT>MIC berperan penting dalam menilai kecukupan terapi, meskipun hubungannya dengan luaran klinis tidak selalu konsisten akibat heterogenitas populasi, derajat keparahan infeksi, dan perbedaan strategi dosis. Paparan vancomycin yang lebih tinggi berkaitan secara konsisten dengan peningkatan risiko nefrotoksisitas. Pendekatan individualisasi berbasis PK/PD melalui therapeutic drug monitoring, Bayesian forecasting, dan model-informed precision dosing terbukti meningkatkan pencapaian target konsentrasi dan menurunkan risiko toksisitas. Kesimpulan: Parameter farmakokinetik klinis berhubungan dengan variabilitas respons antibiotik pada pasien gangguan fungsi ginjal, dengan hubungan yang lebih konsisten terhadap toksisitas dibandingkan efektivitas. Integrasi strategi individualisasi dosis berbasis PK/PD ke dalam praktik klinis rutin diperlukan untuk mengoptimalkan efektivitas dan keamanan terapi antibiotik, didukung oleh pengembangan model prediksi yang komprehensif pada populasi ini.

Unduhan

Data unduhan belum tersedia.

Rincian Artikel

Cara Mengutip
Anggarany , A. D., Wafa, W., & Saputra , R. (2026). The Hubungan Parameter Farmakokinetik Klinis dengan Variabilitas Respons Antibiotik pada Pasien Gangguan Fungsi Ginjal: Suatu Tinjauan Sistematis . Journal of Pharmaceutical and Sciences, 9(3), 2223–2234. https://doi.org/10.36490/journal-jps.com.v9i3.1714
Bagian
Review Article

Referensi

Valladales-Restrepo LF, Henao-Salazar JA, Mejía-Mejía I, Castro-Aragón DA, Rodríguez-Correa N, Oyuela-Gutiérrez MC, et al. Use of antibiotics in patients with chronic kidney disease: evidence from the real world. Expert Opin Drug Saf 2026;25:695–701. https://doi.org/10.1080/14740338.2024.2443780

Liu P, Capitano B, Stein A, El-Solh AA. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis. BMC Nephrol 2017;18:168. https://doi.org/10.1186/s12882-017-0581-y

Ishigo T, Matsumoto K, Yoshida H, Tanaka H, Ibe Y, Fujii S, et al. Relationship between nephrotoxicity and area under the concentration–time curve of vancomycin in critically ill patients: a multicenter retrospective study. Microbiol Spectr 2024;12:e03739-23. https://doi.org/10.1128/spectrum.03739-23.

Matsuki Y, Sako K, Kozima Y, Watanabe T, Kashiwagura Y, Yasuno N, et al. Development and validation of a novel scoring model integrating clinical risk factors and pharmacokinetic parameters to predict vancomycin-induced nephrotoxicity. Pharmacotherapy 2026;46:e70111. https://doi.org/10.1002/phar.70111.

Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJC. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. J Antimicrob Chemother 2017;72:900–905. https://doi.org/10.1093/jac/dkw486.

Udy AA, Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, et al. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents 2017;49:624–630. https://doi.org/10.1016/j.ijantimicag.2016.12.022

Shorr AF, Bruno CJ, Zhang Z, Jensen E, Gao W, Feng HP, et al. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Crit Care 2021;25:354. https://doi.org/10.1186/s13054-021-03773-5.

Zamoner W, de Souza Cavalcante R, Balbi AL, Ponce D. Vancomycin administration and AUC/MIC in patients with acute kidney injury on hemodialysis (HD): randomized clinical trial. Sci Rep 2024;14:31220. https://doi.org/10.1038/s41598-024-82587-1.

Nakagawa R, Sato K, Uesaka Y, Mitsuki T, Kondo K, Wake A, et al. Cefepime-induced encephalopathy in end-stage renal disease patients. J Neurol Sci 2017;376:123–128. https://doi.org/10.1016/j.jns.2017.03.018.

Shahar S, Arimuthu DA, Mazlan SA. Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report. BMC Nephrol 2022;23:360. https://doi.org/10.1186/s12882-022-02980-8.

Zhang Y, Wang T, Zhang D, You H, Dong Y, Liu Y, et al. Therapeutic drug monitoring coupled with Bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis. Ther Drug Monit 2020;42:600–609. https://doi.org/10.1097/FTD.0000000000000750.

Sanz-Codina M, Bozkir HÖ, Jorda A, Zeitlinger M. Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect 2023;29:845–857. https://doi.org/10.1016/j.cmi.2023.03.018

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.

Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, Editors. JBI Manual for Evidence Synthesis. Adelaide: JBI; 2020. https://doi.org/10.46658/JBIMES-20-08.

Wu W, Ke M, Ye L, Lin C. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. Eur J Clin Pharmacol. 2021;77:989–998. https://doi.org/10.1007/s00228-020-03072-y.

Nakashima T, Koido K, Baba H, Otsuka R, Okinaka K, Sano T, Nishigaki R, Hashimoto H, Otsuka T, Esaki M, Terakado H. Contribution of pharmacists with expertise in infectious diseases to appropriate individualized vancomycin dosing. Pharmazie. 2018;73(7):422–424. https://doi.org/10.1691/ph.2018.8427.

Wang X, Wang Y, Yao F, Chen S, Hou Y, Zheng Z, Luo J, Qiu B, Li Z, Wang Y, Wu Z, Lan J, Chen C. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Des Devel Ther. 2021;15:2129–2141. https://doi.org/10.2147/DDDT.S303497.

Wang L, Yuan Q, Tan M, Xie S, Wu J, Song X, Wang C. Evaluation of efficacy and nephrotoxicity during vancomycin therapy: A retrospective study in China. Exp Ther Med. 2019;17(3):2389–2396. https://doi.org/10.3892/etm.2019.7188.

Cheng C, Akter F, Bozell H, Neumann T. Linezolid-induced lactic acidosis presenting as acute cholecystitis: a case report and systematic review. Cureus. 2024;16(10):e70794. https://doi.org/10.7759/cureus.70794.

Aitullina A, Krūmiņa A, Svirskis Š, Purviņa S. Colistin use in patients with extreme renal function: from dialysis to augmented clearance. Medicina (Kaunas). 2019;55(2):33. https://doi.org/10.3390/medicina55020033.

Saad R, Hallit S, Chahine B. Evaluation of renal drug dosing adjustment in chronic kidney disease patients at two university hospitals in Lebanon. Pharm Pract. 2019;17(1):1304.

Hassan Z, Ali I, Ullah AR, Ahmed R, Zar A, Ullah I, et al. Assessment of Medication Dosage Adjustment in Hospitalized Patients With Chronic Kidney Disease. Cureus. 2021;13(2):e13449. https://doi.org/10.7759/cureus.13449.

Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the ASHP, IDSA, PIDS, and SIDP. Am J Health Syst Pharm. 2020;77(11):835–864. https://doi.org/10.1093/ajhp/zxaa036.